MX383792B - Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. - Google Patents

Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Info

Publication number
MX383792B
MX383792B MX2017003436A MX2017003436A MX383792B MX 383792 B MX383792 B MX 383792B MX 2017003436 A MX2017003436 A MX 2017003436A MX 2017003436 A MX2017003436 A MX 2017003436A MX 383792 B MX383792 B MX 383792B
Authority
MX
Mexico
Prior art keywords
eye
protection
drug administration
anterior segment
compound
Prior art date
Application number
MX2017003436A
Other languages
English (en)
Spanish (es)
Other versions
MX2017003436A (es
Inventor
Paul G Chaney
David P Bingaman
Martin B Wax
Original Assignee
Panoptica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panoptica Inc filed Critical Panoptica Inc
Publication of MX2017003436A publication Critical patent/MX2017003436A/es
Publication of MX383792B publication Critical patent/MX383792B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017003436A 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo. MX383792B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462051794P 2014-09-17 2014-09-17
PCT/US2015/050818 WO2016044671A1 (en) 2014-09-17 2015-09-17 Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Publications (2)

Publication Number Publication Date
MX2017003436A MX2017003436A (es) 2017-07-28
MX383792B true MX383792B (es) 2025-03-14

Family

ID=55453708

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017003436A MX383792B (es) 2014-09-17 2015-09-17 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021006070A MX2021006070A (es) 2014-09-17 2017-03-15 Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.

Country Status (18)

Country Link
US (7) US9814702B2 (enExample)
EP (2) EP3193867B1 (enExample)
JP (3) JP6657193B2 (enExample)
KR (2) KR102555091B1 (enExample)
CN (2) CN106999476B (enExample)
AU (2) AU2015317531B2 (enExample)
DK (1) DK3193867T3 (enExample)
ES (2) ES2863601T3 (enExample)
HU (1) HUE053852T2 (enExample)
IL (2) IL282504B (enExample)
MA (1) MA56220A (enExample)
MX (2) MX383792B (enExample)
NZ (1) NZ767710A (enExample)
PL (1) PL3193867T3 (enExample)
PT (1) PT3193867T (enExample)
RU (2) RU2704810C2 (enExample)
WO (1) WO2016044671A1 (enExample)
ZA (1) ZA201701303B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015317531B2 (en) * 2014-09-17 2020-11-19 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye
EP3616723B1 (en) * 2018-07-18 2024-08-07 Wenzhou Medical University Use of nicotinic acid or prazosin for treating myopia
CN113164551A (zh) * 2018-10-24 2021-07-23 雅利斯塔制药公司 脂联素肽模拟物制剂
AU2021322232A1 (en) * 2020-08-05 2023-03-23 TearClear Corp. Systems and methods for preservative removal from ophthalmic formulations
JP2022131565A (ja) * 2021-02-26 2022-09-07 ロート製薬株式会社 水性医薬組成物
KR102633321B1 (ko) * 2021-05-11 2024-02-05 연세대학교 산학협력단 노인성 황반변성의 예방 또는 치료를 위한 약학 조성물
CN115521901B (zh) * 2022-10-12 2023-09-05 中国医学科学院医学生物学研究所 永生化树鼩视网膜微血管内皮细胞株及其构建方法与应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2792997A (en) * 1997-05-26 1998-12-30 New Vision Co., Ltd. Medicinal compositions for topical administration containing vitamin d and vitamin k
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
MXPA03004714A (es) * 2000-11-28 2003-08-19 Pfizer Prod Inc Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion.
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
US20050074497A1 (en) * 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
CN1946352A (zh) * 2004-04-09 2007-04-11 狄科特康坦特公司 递送药物至眼以治疗后段疾病的方法和物品
US20060134226A1 (en) * 2004-11-16 2006-06-22 Todd Leonard Compositions useful to treat ocular neovascular diseases and macular degeneration
WO2007041499A2 (en) * 2005-09-30 2007-04-12 Lipoprotein Technologies, Inc. Cox inhibitor and nicotinic acid compositions and methods
WO2009129859A1 (en) * 2008-04-24 2009-10-29 Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh Compositions and methods for maintaining, strengthening, improving, or promoting eye health
CN105362221A (zh) * 2009-03-03 2016-03-02 爱尔康研究有限公司 向眼部递送受体酪氨酸激酶抑制性(RTKi)化合物的药物组合物
WO2011019678A1 (en) * 2009-08-11 2011-02-17 Allergan, Inc. Isothiozoles for treating conditions of the eye
KR20120100964A (ko) * 2009-09-30 2012-09-12 바이타패스 제네틱스 인코포레이티드 개인용 보조인자 및 사용 방법
JP2013531067A (ja) * 2010-07-19 2013-08-01 バイエル ヘルスケア リミティド ライアビリティ カンパニー 疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
JP5956992B2 (ja) * 2010-08-17 2016-07-27 オーエイチアール・ファーマシューティカル・インコーポレイテッドＯｈｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌ，Ｉｎｃ． スクアラミンの眼用製剤
EP2444063A1 (en) * 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
US20110052678A1 (en) * 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20140161720A1 (en) * 2011-05-26 2014-06-12 The General Hospital Corporation Treatment of angiogenic- or vascular-associated diseases
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ２型の懸濁剤
HK1205461A1 (zh) * 2012-02-22 2015-12-18 Trustees Of Tufts College 用於眼部传输治疗剂的组合物和方法
KR102433489B1 (ko) 2013-03-14 2022-08-17 팬옵티카, 인크. 눈의 후안부로의 약물 전달을 위한 안구용 제제
AU2015317531B2 (en) * 2014-09-17 2020-11-19 Panoptica, Inc. Ocular formulations for drug-delivery and protection of the anterior segment of the eye

Also Published As

Publication number Publication date
MX2017003436A (es) 2017-07-28
US20190314343A1 (en) 2019-10-17
RU2768652C1 (ru) 2022-03-24
DK3193867T3 (da) 2021-04-06
MX2021006070A (es) 2021-07-06
JP7176042B2 (ja) 2022-11-21
EP3193867B1 (en) 2021-01-20
EP3193867A4 (en) 2018-05-02
KR20170058976A (ko) 2017-05-29
ES2863601T3 (es) 2021-10-11
JP6890692B2 (ja) 2021-06-18
AU2015317531B2 (en) 2020-11-19
IL282504A (en) 2021-06-30
WO2016044671A1 (en) 2016-03-24
JP2021121624A (ja) 2021-08-26
NZ767710A (en) 2023-09-29
RU2704810C2 (ru) 2019-10-31
RU2017112930A (ru) 2018-10-17
ES3010497T3 (en) 2025-04-03
IL251019B (en) 2021-05-31
HUE053852T2 (hu) 2021-07-28
US10183014B2 (en) 2019-01-22
BR112017005523A2 (pt) 2017-12-05
CN113209000A (zh) 2021-08-06
US20160206599A1 (en) 2016-07-21
KR20220137157A (ko) 2022-10-11
NZ729142A (en) 2023-08-25
US9623011B2 (en) 2017-04-18
US20210275501A1 (en) 2021-09-09
US9814702B2 (en) 2017-11-14
AU2021200997A1 (en) 2021-03-11
KR102450020B1 (ko) 2022-09-30
US20180078531A1 (en) 2018-03-22
AU2015317531A1 (en) 2017-03-09
AU2021200997B2 (en) 2023-02-02
RU2017112930A3 (enExample) 2019-04-11
KR102555091B1 (ko) 2023-07-13
US20240277674A1 (en) 2024-08-22
US20160074371A1 (en) 2016-03-17
US20260048039A1 (en) 2026-02-19
PT3193867T (pt) 2021-03-09
EP3878449B1 (en) 2024-10-30
PL3193867T3 (pl) 2021-07-12
CN106999476A (zh) 2017-08-01
CA2958315A1 (en) 2016-03-24
EP3193867A1 (en) 2017-07-26
IL282504B (en) 2022-08-01
EP3878449A1 (en) 2021-09-15
ZA201701303B (en) 2021-07-28
JP2017527600A (ja) 2017-09-21
JP6657193B2 (ja) 2020-03-04
IL251019A0 (en) 2017-04-30
JP2020079274A (ja) 2020-05-28
CN106999476B (zh) 2021-05-04
CN113209000B (zh) 2025-05-13
MA56220A (fr) 2022-04-20

Similar Documents

Publication Publication Date Title
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2021006070A (es) Formulaciones oculares para la administracion de farmacos y proteccion del segmento anterior del ojo.
PH12018500586B1 (en) Farnesoid x receptor agonists and uses thereof
MX2015013396A (es) Derivados de quinolinas como nuevos agentes contra el cancer.
MX378707B (es) Compuestos para el tratamiento de enfermedades y trastornos oftalmicos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
PH12016500582B1 (en) Heterocyclic compounds and uses thereof
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
HK1207069A1 (en) Heterocyclic compounds and uses thereof
MX387235B (es) Derivados de pirazolopiridina y su uso en terapia
PH12015501942A1 (en) Susbtituted 3-phenylpropylamine derivatives for the treatment of opthalmic diseases and disorders
CL2016002091A1 (es) Compuesto de triazina y su uso para fines medicinales
PH12017500810A1 (en) Substituted 2,4 diamino-quinoline as new anticancer agents
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MY199091A (en) Therapeutic compounds
EP3334719A4 (en) SUBSTITUTED BENZIMIDAZOLE, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EP4420722A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
EP3167893A4 (en) Pharmaceutical composition containing spirulina maxima extract as active ingredient for preventing and treating retinal diseases
PH12015502564A1 (en) Pyridone derivatives for the treatment of viral infections and further diseases
PH12019500024A1 (en) Pharmaceutical compositions
GT201600072A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il)pirimidin-4-il]-4(1h-1,2,3-triazol-1-il)-1h-pirazol-5-olato de sodio
EP3187179A4 (en) Pharmaceutical composition for prophylaxis and/or treatment of corneal and conjunctival diseases or presbyopia containing stilbene compound as active ingredient
CR20160177A (es) Formas de dosificación farmacéutica que comprenden 1-[6-(morfolin-4-il) pirimidin-4-il]-4-(1h-1,2,3-triazol-1-il)1h-pirazol-5-olato de sodio
MX2015012393A (es) Derivados oxindol con un sustituyente oxetano y uso de los mismos para tratar enfermedades relacionadas con la vasopresina.